Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2019-07-16 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate from the National Medical Products Administration. It details the certificate specifics, related products, impact on company performance, and risk warnings. The document is short (1041 characters) and does not contain financial statements or detailed financial data. It is an official announcement about a regulatory approval rather than a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2019-07-16 Chinese
关于控股子公司完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the completion of a business registration change for its controlling subsidiary, Beijing Antu Bioengineering Co., Ltd. It details the new business license information such as company name, address, legal representative, registered capital, and business scope. There is no financial data, no mention of annual or quarterly reports, no voting results, no executive changes, or other report types. The document is a regulatory announcement about a corporate administrative change. It fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2019-07-05 Chinese
关于控股子公司完成医疗器械生产许可证变更登记的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the completion of a change in the medical device production license registration for its controlling subsidiary. It details the updated company name, production address, license number, and other administrative information. There is no financial data, no mention of financial results, no shareholder voting, no management changes, no legal proceedings, and no report attachments. The document is a regulatory announcement about a license change, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2019-07-05 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from a regulatory authority (Henan Provincial Drug Administration). It details product registration numbers, intended uses, R&D investment, and potential impact on company performance. The document is short (955 characters) and is an announcement of a regulatory approval rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-07-05 Chinese
独立董事关于公司第三届董事会第七次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent directors' opinion on several proposals related to the use of raised funds by the company, including replacement of self-raised funds, cash management of idle raised funds, and capital increase and loans to subsidiaries for investment projects. It references compliance with regulatory guidelines on the management and use of raised funds, and it is dated July 4, 2019. The document is a formal opinion letter from independent directors rather than a full financial report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a notice of voting results or a proxy solicitation. It is a regulatory compliance opinion related to fundraising and use of proceeds, which fits best under Regulatory Filings (RNS) as it does not meet criteria for other specific categories like Capital/Financing Update (CAP) or Management Reports (MDA). The document length is short (1140 characters), and it is not an announcement of a report publication but an independent opinion letter.
2019-07-04 Chinese
关于使用募集资金置换预先投入自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of raised funds to replace previously invested self-raised funds in investment projects. It details the amount of convertible bonds issued, the use of proceeds, approval procedures, and includes opinions from the board, independent directors, supervisors, and the sponsoring institution. The document is focused on the company's capital raising and the use of those funds, specifically the replacement of self-raised funds with raised funds. It does not contain financial statements or comprehensive financial performance data, nor is it a report or presentation. It is an update on financing activities related to the company's capital structure and use of proceeds. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3253 characters, which is consistent with an announcement rather than a full report.
2019-07-04 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.